JP5144532B2 - ｃ−Ｍｅｔ阻害剤及び用法 - Google Patents

ｃ−Ｍｅｔ阻害剤及び用法 Download PDF

Info

Publication number
JP5144532B2
JP5144532B2 JP2008543461A JP2008543461A JP5144532B2 JP 5144532 B2 JP5144532 B2 JP 5144532B2 JP 2008543461 A JP2008543461 A JP 2008543461A JP 2008543461 A JP2008543461 A JP 2008543461A JP 5144532 B2 JP5144532 B2 JP 5144532B2
Authority
JP
Japan
Prior art keywords
aliphatic
compound
ring
optionally substituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008543461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518296A (ja
JP2009518296A5 (enExample
Inventor
デイビッド ラウファー，
アレクサンダー アロノブ，
パン リー，
デイビッド デニンジャー，
キラ マギンティ，
ディーン スタモス，
ジョン カム，
ミシェル スチュワート，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2009518296A publication Critical patent/JP2009518296A/ja
Publication of JP2009518296A5 publication Critical patent/JP2009518296A5/ja
Application granted granted Critical
Publication of JP5144532B2 publication Critical patent/JP5144532B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2008543461A 2005-11-30 2006-11-30 ｃ−Ｍｅｔ阻害剤及び用法 Expired - Fee Related JP5144532B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US74074105P 2005-11-30 2005-11-30
US74085905P 2005-11-30 2005-11-30
US74073705P 2005-11-30 2005-11-30
US60/740,741 2005-11-30
US60/740,737 2005-11-30
US60/740,859 2005-11-30
PCT/US2006/045847 WO2007064797A2 (en) 2005-11-30 2006-11-30 Inhibitors of c-met and uses thereof

Publications (3)

Publication Number Publication Date
JP2009518296A JP2009518296A (ja) 2009-05-07
JP2009518296A5 JP2009518296A5 (enExample) 2012-11-22
JP5144532B2 true JP5144532B2 (ja) 2013-02-13

Family

ID=37998312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008543461A Expired - Fee Related JP5144532B2 (ja) 2005-11-30 2006-11-30 ｃ−Ｍｅｔ阻害剤及び用法

Country Status (12)

Country Link
US (2) US7728017B2 (enExample)
EP (1) EP1963329B1 (enExample)
JP (1) JP5144532B2 (enExample)
KR (1) KR20080080584A (enExample)
AU (1) AU2006320580B2 (enExample)
BR (1) BRPI0619252A2 (enExample)
CA (1) CA2630884A1 (enExample)
IL (1) IL191623A0 (enExample)
MX (1) MX2008007049A (enExample)
NO (1) NO20082880L (enExample)
NZ (1) NZ568666A (enExample)
WO (1) WO2007064797A2 (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
WO2007147217A1 (en) * 2006-06-22 2007-12-27 Prana Biotechnology Limited Method of treatment of glioma brain tumour
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
EP2046336A4 (en) * 2006-07-18 2010-12-15 Cytovia Inc 3-ARYL-6-ARYL-7H- [1,2,4] TRIAZOLO [3,4-B] [1,3,4] THIADIAZINE AND ANALOGUE AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCTORS AND THEIR USE
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
WO2008036272A1 (en) * 2006-09-18 2008-03-27 Vertex Pharmaceuticals Incorporated HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
ES2560435T3 (es) 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
EP2137162B1 (en) * 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
KR101156845B1 (ko) * 2007-05-21 2012-06-18 에스지엑스 파마슈티컬스, 인코포레이티드 헤테로시클릭 키나제 조절제
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2929613B1 (fr) * 2008-04-02 2010-12-31 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
FR2919870B1 (fr) * 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
EP2193133B1 (en) 2007-09-27 2015-08-19 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Imidazolothiadiazoles for use as protein kinase inhibitors
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
MX393622B (es) 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
CN102216309B (zh) 2008-11-19 2014-05-07 沃泰克斯药物股份有限公司 C-met蛋白激酶的三唑并噻二唑抑制剂
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
MX2011006682A (es) 2008-12-22 2011-07-13 Merck Patent Gmbh Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
DE102008062825A1 (de) * 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
CN102388048B (zh) 2009-02-10 2014-07-30 阿斯利康(瑞典)有限公司 三唑并[4，3-b]哒嗪衍生物及其用于前列腺癌的用途
CA2754180A1 (en) 2009-03-09 2010-09-16 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
ES2548571T3 (es) 2009-04-02 2015-10-19 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Derivados de imidazo[2,1-b][1,3,4]tiadiazol
EP2435444A1 (en) 2009-05-28 2012-04-04 Vertex Pharmaceuticals Incorporated Substituted pyrazole inhibitors of c-met protein kinase
JP2012528188A (ja) * 2009-05-28 2012-11-12 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼの阻害剤
DK2435443T3 (da) * 2009-05-28 2013-10-28 Vertex Pharma Aminopyrazoltriazolothiadiazolhæmmere af c-met-proteinkinase
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
RS61281B1 (sr) * 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP3450432A1 (en) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US8263777B2 (en) 2010-05-27 2012-09-11 Vertex Pharmaceuticals Incorporated Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
GEP201706656B (en) 2011-11-11 2017-04-25 Pfizer 2-thiopyrimidinones
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
TW201341367A (zh) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc ３，５－二胺基吡唑激酶抑制劑
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
ES2660249T3 (es) 2012-12-20 2018-03-21 Inception 2, Inc. Compuestos de tipo triazolona y sus usos
JP2016529311A (ja) 2013-09-06 2016-09-23 インセプション ２、 インコーポレイテッド トリアゾロン化合物類及びそれらの使用
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
AU2013402175B2 (en) 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3285764B1 (en) * 2015-03-31 2024-03-27 University of Vermont and State Agricultural College Triazolopyridazines for treating cryptosporidiosis
MA42035A (fr) 2015-05-05 2018-03-14 Pfizer 2-thiopyrimidinones
SG10201912684TA (en) * 2015-06-25 2020-03-30 Taiho Pharmaceutical Co Ltd Therapeutic agent for fibrosis
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
PE20181197A1 (es) 2015-10-14 2018-07-23 Bristol Myers Squibb Co 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
BR112018010720A8 (pt) 2015-12-04 2019-02-26 Bristol Myers Squibb Co agonistas do receptor de apelina e métodos de uso
ES2854733T3 (es) 2015-12-16 2021-09-22 Bristol Myers Squibb Co Heteroarilhidroxipirimidinonas como agonistas del receptor APJ
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
GR1009565B (el) * 2016-07-14 2019-08-06 Galenica Α.Ε. Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
ES2909086T3 (es) 2017-01-11 2022-05-05 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
MX2021007061A (es) 2017-02-15 2022-10-07 Taiho Pharmaceutical Co Ltd Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina.
JP6915907B2 (ja) * 2017-05-26 2021-08-04 江▲蘇▼新元素医▲薬▼科技有限公司Ｊｉａｎｇｓｕ Ａｔｏｍ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 尿酸排泄を促進するｕｒａｔ１阻害剤
EP3652165B1 (en) * 2017-07-12 2021-08-25 Bristol-Myers Squibb Company Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
SG11202000970WA (en) 2017-08-07 2020-02-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase
WO2019049956A1 (ja) 2017-09-08 2019-03-14 大鵬薬品工業株式会社 抗腫瘍剤及び抗腫瘍効果増強剤
WO2019178129A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
TR202009388A1 (tr) * 2020-06-17 2021-12-21 Anadolu Ueniversitesi Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
TR202010296A1 (tr) 2020-06-30 2022-01-21 Anadolu Ueniversitesi Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
JP2024510504A (ja) * 2021-03-17 2024-03-07 武田薬品工業株式会社 血漿カリクレインの多環式インヒビター

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
HUE030390T2 (en) * 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators

Also Published As

Publication number Publication date
MX2008007049A (es) 2008-10-23
WO2007064797A2 (en) 2007-06-07
AU2006320580A1 (en) 2007-06-07
US7998987B2 (en) 2011-08-16
BRPI0619252A2 (pt) 2011-09-20
KR20080080584A (ko) 2008-09-04
AU2006320580B2 (en) 2011-06-23
JP2009518296A (ja) 2009-05-07
US20100190774A1 (en) 2010-07-29
NZ568666A (en) 2011-09-30
US7728017B2 (en) 2010-06-01
NO20082880L (no) 2008-09-01
CA2630884A1 (en) 2007-06-07
IL191623A0 (en) 2008-12-29
WO2007064797A3 (en) 2007-12-13
EP1963329B1 (en) 2013-01-23
EP1963329A2 (en) 2008-09-03
US20070191369A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
JP2009518296A (ja) ｃ−Ｍｅｔ阻害剤及び用法
EP1881983B1 (en) Pyrrolopyridines useful as inhibitors of protein kinase
CA3150515A1 (en) PRMT5 INHIBITORS IN COOPERATION WITH MTA
US20060122185A1 (en) Bicyclic inhibitors of Rho kinase
EP2001884A1 (en) Deazapurines useful as inhibitors of janus kinases
US8481538B2 (en) Heterocyclic inhibitors of c-Met and uses thereof
KR20070104641A (ko) 단백질 키나제의 억제제로 유용한 피롤로피리미딘
KR20110039383A (ko) ｃＭＥＴ 억제제
JP2010508363A (ja) ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物
KR20110039278A (ko) 단백질 키나제 억제제
WO2009085913A1 (en) PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS
NZ575346A (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
CN101778825A (zh) 适用作詹纳斯激酶抑制剂的n-杂环类化合物
CN101360748B (zh) c-MET抑制剂及其应用
HK1125106A (en) Inhibitors of c-met and uses thereof
HK1146825A (en) Heterocyclic inhibitors of c-met and uses thereof
HK1138587A (en) Thiazoles and pyrazoles useful as kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120710

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121030

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121122

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151130

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees